Division of Clinical Research

Office of the Vice President and Innovation

Category results for: COVID-19

OMH Virtual Symposium on COVID-19

Registration is now open for Advancing the Response to COVID-19: Sharing Promising Programs and Practices for Racial and Ethnic Minority Communities, a virtual symposium hosted by the U.S Department of Health and Human Services (HHS) Office of Minority Health (OMH) taking place on September 17, 2020. Join us to learn from national, state, tribal and local experts […]

FDA Insight Podcast

Join Dr. Anand Shah, FDA’s Deputy Commissioner for Medical and Scientific Affairs, and other FDA leaders as they provide their insight into issues facing the agency – including the COVID-19 pandemic and other emerging topics. New episodes on Tuesdays! Ep. 1: Fighting COVID-19 at the FDA Ep 2: All About COVID-19 Testing Ep 3: Food […]

Webinar on FDA’s Regulation of Face Masks and Surgical Masks During the COVID-19 Pandemic

On Tuesday, August 4, 12:00 p.m.-1:00 p.m. ET, the U.S. Food and Drug Administration (FDA) will host a webinar on the FDA’s regulation of face masks and surgical masks during the COVID-19 pandemic. This webinar will expand the scope of the respirator webinar series to discuss face masks and surgical masks. During this webinar, representatives […]

August Dates Announced for the FDA’s Virtual Town Hall for Labs and Manufacturers on Coronavirus (COVID-19) Diagnostic Tests

In August, the U.S. Food and Drug Administration (FDA) will continue hosting virtual Town Halls for clinical laboratories and commercial manufacturers that are developing or have developed diagnostic tests for SARS-CoV-2 on the following dates: August 5, 2020 from 12:15 pm – 1:15 pm Eastern Time August 12, 2020 from 12:15 pm – 1:15 pm […]

How FDA is Working to Facilitate COVID-19 Treatments

When the FDA learned of the novel coronavirus (COVID-19) and its potentially devastating effects, we acted swiftly to set the regulatory stage for drug and biologics manufacturers to develop products to treat this serious disease. To meet this urgent need, the FDA created the Coronavirus Treatment Acceleration Program (CTAP) to enable the FDA’s Center for […]

FDA Updates Question-and-Answer Appendix in Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Public Health Emergency

(7/2/2020) The U.S. Food and Drug Administration updated content to the question-and-answer appendix in its guidance titled “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency.” This guidance is intended for industry, investigators and institutional review boards. The updated guidance clarifies two previously suggested methods for obtaining informed consent from a hospitalized […]

July One VCU Clinical Research Teams Meeting

Tuesday, July 14, 2020 from 9:00 a.m. – 9:50 a.m. Topics: Human Research Protections – resources/ location of information  VCU Health Clinical areas – how to stay up to date and how to check in to get PPE needed  COVID-19 clinical trial update and lessons learned  eTools for remote productivity  How to navigate the R2R […]

New Free CITI Program Course COVID-19: Back to Campus (Fall 2020)

AAMC and CITI Program have collaborated to launch a complimentary course to train staff, students, and faculty on COVID-19 safety, for their return to campus. AAMC and CITI Program have collaborated to launch a complimentary course to train staff, students, and faculty on COVID-19 safety, for their return to campus. The course was made possible […]

Research Return to VCUHS

Please see the following information regarding infection prevention, PPE and cleaning/disinfecting protocols for VCUHS return to research. For more information, please visit the VCUHS Intranet COVID19 Home Page. Patient Screening:All research patients must be screened prior to their visit or signs/symptoms. If they are symptomatic, then their visit is postponed until they are feeling better […]

Federal Government Issues warnings over threats to COVID-19 research

Recently, federal agencies (FBI and CISA) issued a PSA for awareness of threats involved in conducting COVID-19-related research. Targeting and compromising of U.S. organizations has been identified.   Activities observed include, attempting to identify and illicitly obtain valuable intellectual property (IP) and public health data related to vaccines, treatments, and testing from networks and personnel affiliated […]

« Previous Page
Next Page »

Follow this blog